Shares of Actinium Pharmaceuticals (ATNM) have moved significantly higher over the past month as investors are starting to come to grips with the potential for the company’s two pipeline products, Iomab-B and Actimab-A, both under investigation for the treatment of acute myeloid leukemia (AML). Iomab-B and Actimab-A are specific anti-cancer monoclonal antibodies (mAb) conjugated to alpha…
Last month I wrote a detailed article introducing investors to 22nd Century Group, Inc. (NYSEMKT:XXII), a Clarence, NY-based biopharmaceutical company founded in 1998 with proprietary technology in nicotine biosynthesis and tobacco plant-biotechnology. The company is engaged in the development and commercialization of tobacco harm reduction cigarettes and smoking cessation products, as well as the contract…
Last week, Gilead Sciences entered into a global partnership for the development and commercialization of filgotinib, a JAK1-selective inhibitor for inflammatory conditions, with Galapagos NV. Galapagos will receive an upfront payment of $725 million consisting of a cash license fee of $300 million and a $425 million equity investment. In addition, Galapagos is eligible for payments up to $1.35…
On December 14, 2015, Immune Pharmaceuticals (IMNP) provided a brief update for investors on the status of its preclinical bi-specific antibodies platform. As a reminder, outside of the lead immuno-inflammation focus with Phase 2 Bertilimumab for Bullous Pemphigoid and Ulcerative Colitis, Immune has a preclinical immuno-oncology program that consists of NanomAbs and bi-specific antibodies. Investors…
Yes, investors, there are still millions of people who smoke cigarettes! Bafflingly, despite all the science and meta-analyses, U.S. Surgeon General warnings and CDC case studies, the World Health Organization (WHO) estimates 5.6 trillion cigarettes were sold globally in 2014. Forty percent of these sales took place in Asia, where roughly two-thirds of the population…
Actinium Pharmaceuticals (NYSEMKT: ATNM) had a very successful showing at the American Society of Hematology (ASH) annual meeting held over the past few days in Orlando, FL. The highlight of the event for the company was a poster presentation of Phase 1 clinical data with Actimab-A, the company’s CD33 targeting alpha particle immunotherapy for the…
Acute Leukemia – A Quick Overview Leukemias are cancers of the blood and involve bone marrow, circulating white blood cells, and organs such as the spleen and lymph nodes. The cancer usually manifests in the bone marrow and results in a high number of abnormal white blood cells called blasts (also called leukemia cells). The…
I’m long Depomed (DEPO). Here is my model: Depomed has now raised guidance two quarters in a row (Q2, Q3). I think the current guidance is still conservative. Management is guiding to revenues between $336 million and $348 million for 2015. I model $344 million, with most of the growth coming from Nucynta / ER. Upside…
RedHill Biopharma Ltd (RDHL) continues to intrigue me from an investment standpoint. In October, I wrote an article detailing the company’s Phase 3 triple-antibiotic therapy for the treatment of Crohn’s disease. Investors can view that article >> HERE <<. In that article, I also provided a quick background on the company and briefly mentioned two other…
“Though this be madness, yet there is method in ’t” – Hamlet: Act II, Sc 2 If you watch a lot of television, especially things like the National Football League (NFL) or PGA Tour golf, or even CNBC, it is virtually impossible to go through a sitting without seeing a commercial for an erectile dysfunction…